NGM Bio hits endpoint in Phase 2 NASH study

03:15 EDT 16 Apr 2018 | BioPharmaDive

The biotech's engineered hormone drug rapidly reduced liver fat and fibrosis in patients with liver disease. The next step will be a Phase 2b study in NASH patients later this year.

Original Article: NGM Bio hits endpoint in Phase 2 NASH study


More From BioPortfolio on "NGM Bio hits endpoint in Phase 2 NASH study"

Quick Search


Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Diabetes Diabetes Endocrine Obesity Oxycontin Renal Disease Thyroid Disorders Endocrinology is the study of the endocrine glands and the hormones that they secrete (Oxford Medical Dictionary). There are several groups of h...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...